Thus, the authors propose that γδ T cytotoxic function is achieved through a two-step process (a TCR stimulation presumably by endogenous phophoantigens and a tumor cell recognition by NKG2D) and that ULBP1 could be used as a leukemia/lymphoma biomarker in clinical trials (49). This evidence concerns the gene KLRK1 and leukemia.